Trial description
A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (Only cohort for Triple Negative Breast Cancer remains open)
Contact name
Dr Richard Baird
Trial start date
Tuesday, April 11, 2017
Trial end date
Thursday, December 31, 2020
Trial tumour type
Show on Radiotherapy